Biostem Technologies

Biostem Technologies FCF/Debt

The Free Cash Flow to Debt Ratio of Biostem Technologies (BSEM) as of Oct 9, 2026 is 16,033.39 %. In the previous year, Free Cash Flow to Debt Ratio was -1,396.39 % — a change of -1,248.21% (higher).

FCF/Debt

16,033.39 %

YoY

-1,248.21%

Last updated:

Free Cash Flow to Debt Ratio of Biostem Technologies is 2024 16,033.39 % . Free Cash Flow to Debt Ratio of Biostem Technologies was 2023 -1,396.39 % . It decreases by -1,248.21% higher compared to the previous year.

The Biostem Technologies FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-824.87 USD
Jan 1, 2019
-107.11 USD
Jan 1, 2020
-44.05 USD
Jan 1, 2021
-8.47 USD
Jan 1, 2022
-183.20 USD
Jan 1, 2023
-1,396.39 USD
Jan 1, 2024
16,033.39 USD
The Biostem Technologies FCF/Debt history
YEARFCF/DebtYoY
16,033.39 %-1,248.21%
-1,396.39 %+662.20%
-183.20 %+2,062.75%
-8.47 %-80.77%
-44.05 %-58.87%
-107.11 %-87.01%
-824.87 %—
Access this data via the Eulerpool API

Biostem Technologies Stock analysis

What does Biostem Technologies do? Biostem Technologies Inc is a US company specializing in regenerative medicine. It was founded in 2007 and is based in Clearwater, Florida. Biostem Technologies is listed on the OTCQB Stock Exchange and offers a wide range of products in the field of regenerative medicine. The company's business model primarily involves advancing growth in the field of regenerative medicine through the development and marketing of new products and technologies. They focus on the production of stem cells that can be used in the regeneration of damaged tissues and organs. They also offer research and development of stem cell therapies, manufacturing of stem cell products, and related services. Biostem Technologies places emphasis on processing umbilical cord blood stem cells, collaborating with medical facilities to collect and isolate these cells for preservation. The company has also developed products such as BioStem Serum and BioStem Gel, made from stem cells and used in regeneration and wound healing. They have developed technologies for regenerating damaged tissues and organs, including a technology for regenerating muscle and adipose tissue through stem cell injection. Clinical studies have shown promising results with this technology. Biostem Technologies has partnerships with other companies and institutes in the field of regenerative medicine, including working with the National Institute of Neurological Disorders and Stroke to develop a new therapy for multiple sclerosis. They also provide consulting services to assist other companies in developing regenerative products and services. In conclusion, Biostem Technologies is a leading company in the field of regenerative medicine and stem cell therapies, offering a range of products and services. They also provide important technologies for tissue regeneration, positioning them as a key player in the field of regenerative medicine. Biostem Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostem Technologies stock

Free Cash Flow to Debt Ratio of Biostem Technologies is 16,033.39 % in 2024.

Free Cash Flow to Debt Ratio of Biostem Technologies changed from -1,396.39 % to 16,033.39 %, representing a -1,248.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Biostem Technologies since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Biostem Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Biostem Technologies

All Key Metrics — Biostem Technologies